{"id":2166,"date":"2026-07-17T14:21:21","date_gmt":"2026-07-17T11:21:21","guid":{"rendered":"https:\/\/reocell.com\/?p=2166"},"modified":"2026-07-17T14:37:55","modified_gmt":"2026-07-17T11:37:55","slug":"quality-control-of-mesenchymal-stem-cells-donor-selection-genetic-stability-and-proliferative-potential","status":"publish","type":"post","link":"https:\/\/reocell.com\/en\/blog\/quality-control-of-mesenchymal-stem-cells-donor-selection-genetic-stability-and-proliferative-potential\/","title":{"rendered":"Quality Control of Mesenchymal Stem Cells: Donor Selection, Genetic Stability, and Proliferative Potential"},"content":{"rendered":"<p><span style=\"font-weight: 400;\">In modern regenerative medicine, <\/span><b>mesenchymal stem cells (MSCs)<\/b><span style=\"font-weight: 400;\"> represent one of the most promising therapeutic platforms, offering new opportunities for the treatment of traumatic injuries, degenerative disorders, and autoimmune diseases. However, the clinical effectiveness of MSC-based therapy depends primarily on the quality of the starting material and strict compliance with internationally recognized manufacturing standards.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Comprehensive quality control includes:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">phenotypic and functional characterization of MSCs;<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">assessment of molecular markers of multipotency;<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">verification of sterility, safety, and genetic stability.<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">The <\/span><b>International Society for Cell &amp; Gene Therapy (ISCT)<\/b><span style=\"font-weight: 400;\"> has established minimum criteria for defining human mesenchymal stem cells. According to these recommendations, MSCs must meet four key requirements.<\/span><\/p>\n<h2><b>Plastic Adherence<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">MSCs must adhere to standard tissue culture plastic under conventional laboratory conditions. This characteristic enables their isolation, expansion, and evaluation throughout the manufacturing process.<\/span><\/p>\n<h2><b>Cellular Identity<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">MSC identity is confirmed by a characteristic immunophenotypic profile, including:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">positive expression of <\/span><b>CD90, CD73, and CD105<\/b><span style=\"font-weight: 400;\">;<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">absence of hematopoietic markers (<\/span><b>CD45<\/b><span style=\"font-weight: 400;\"> and <\/span><b>CD34<\/b><span style=\"font-weight: 400;\">);<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">absence of monocyte\/macrophage markers (<\/span><b>CD14<\/b><span style=\"font-weight: 400;\"> or <\/span><b>CD11b<\/b><span style=\"font-weight: 400;\">);<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">absence of B-cell markers (<\/span><b>CD19<\/b><span style=\"font-weight: 400;\"> or <\/span><b>CD79a<\/b><span style=\"font-weight: 400;\">);<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">absence of <\/span><b>HLA-DR<\/b><span style=\"font-weight: 400;\"> expression.<\/span><\/li>\n<\/ul>\n<h2><b>Multipotent Differentiation<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">MSCs must demonstrate the ability to differentiate <\/span><i><span style=\"font-weight: 400;\">in vitro<\/span><\/i><span style=\"font-weight: 400;\"> into three mesenchymal lineages:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">osteoblasts (bone cells);<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">adipocytes (fat cells);<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">chondroblasts\/chondrocytes (cartilage cells).<\/span><\/li>\n<\/ul>\n<h2><b>Purity<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">The final cellular product must consist of a homogeneous MSC population and be free from microbial contamination, endotoxins, mycoplasma, and other biological contaminants.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">At <\/span><b>ReoCell<\/b><span style=\"font-weight: 400;\">, strict adherence to these international quality criteria ensures the safety, consistency, and therapeutic potential of every MSC product used in clinical practice.<\/span><\/p>\n<h1><b>Multistage Donor Selection: The Foundation of Cell Quality<\/b><\/h1>\n<p><span style=\"font-weight: 400;\">The biological quality of an MSC product begins with donor selection. At ReoCell, donors undergo a comprehensive multistage evaluation based on biological, medical, and epidemiological criteria.<\/span><\/p>\n<h2><b>Donor Age and Its Impact on Cell Quality<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">Donor age is one of the most important determinants of MSC quality. Numerous studies have demonstrated a strong correlation between donor age and the biological potential of mesenchymal stem cells.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Young MSCs possess longer <\/span><b>telomeres<\/b><span style=\"font-weight: 400;\">\u2014protective DNA structures located at the ends of chromosomes\u2014which gradually shorten with each cell division. Aging is also associated with the accumulation of epigenetic modifications, including DNA methylation and histone acetylation, that progressively reduce regenerative capacity.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">For this reason, ReoCell selects donors between <\/span><b>20 and 35 years of age<\/b><span style=\"font-weight: 400;\">, helping preserve the highest regenerative potential of harvested MSCs.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">MSCs obtained from young donors typically demonstrate:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">high expression of genes associated with multipotency;<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">low baseline expression of pro-inflammatory cytokines;<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">an optimal epigenetic profile;<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">high proliferative capacity, supporting tissue renewal and regeneration;<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">a low risk of replicative senescence;<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">enhanced functional activity;<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">high secretory activity, including the release of growth factors and extracellular vesicles.<\/span><\/li>\n<\/ul>\n<h1><b>Screening for Blood-Borne Infections: A Fundamental Safety Requirement<\/b><\/h1>\n<p><span style=\"font-weight: 400;\">Ensuring the absence of blood-borne pathogens is a critical component of donor screening. At ReoCell, molecular diagnostic methods based on <\/span><b>polymerase chain reaction (PCR)<\/b><span style=\"font-weight: 400;\"> are used as part of <\/span><b>Nucleic Acid Testing (NAT)<\/b><span style=\"font-weight: 400;\"> to detect viral genetic material at the earliest possible stage of infection.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Compared with conventional serological testing, NAT methods can identify viral nucleic acids during the <\/span><b>serological window period<\/b><span style=\"font-weight: 400;\">, significantly reducing the risk of undetected infection.<\/span><\/p>\n<table style=\"width:100%;border-collapse:collapse;margin:1.5em 0;font-size:.95em\">\n<thead>\n<tr>\n<th style=\"border:1px solid #d0d0d0;padding:10px 12px;text-align:left;background:#f5f5f5;font-weight:600\">Pathogen<\/th>\n<th style=\"border:1px solid #d0d0d0;padding:10px 12px;text-align:left;background:#f5f5f5;font-weight:600\">Detection Window (NAT)<\/th>\n<th style=\"border:1px solid #d0d0d0;padding:10px 12px;text-align:left;background:#f5f5f5;font-weight:600\">Detection Window (Serology)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #d0d0d0;padding:10px 12px;vertical-align:top\">HIV-1<\/td>\n<td style=\"border:1px solid #d0d0d0;padding:10px 12px;vertical-align:top\">8\u201333 days<\/td>\n<td style=\"border:1px solid #d0d0d0;padding:10px 12px;vertical-align:top\">18\u201345 days<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #d0d0d0;padding:10px 12px;vertical-align:top;background:#fafafa\">Hepatitis B virus (HBV)<\/td>\n<td style=\"border:1px solid #d0d0d0;padding:10px 12px;vertical-align:top;background:#fafafa\">5\u201310 days<\/td>\n<td style=\"border:1px solid #d0d0d0;padding:10px 12px;vertical-align:top;background:#fafafa\">30\u201360 days<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #d0d0d0;padding:10px 12px;vertical-align:top\">Hepatitis C virus (HCV)<\/td>\n<td style=\"border:1px solid #d0d0d0;padding:10px 12px;vertical-align:top\">4\u201310 days<\/td>\n<td style=\"border:1px solid #d0d0d0;padding:10px 12px;vertical-align:top\">15\u201390 days<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #d0d0d0;padding:10px 12px;vertical-align:top;background:#fafafa\">Human T-cell leukemia virus (HTLV)<\/td>\n<td style=\"border:1px solid #d0d0d0;padding:10px 12px;vertical-align:top;background:#fafafa\">15\u201360 days<\/td>\n<td style=\"border:1px solid #d0d0d0;padding:10px 12px;vertical-align:top;background:#fafafa\">30\u2013180 days<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><span style=\"font-weight: 400;\">Donors with positive screening results are excluded from the donation program or undergo repeat testing after an appropriate follow-up interval.<\/span><\/p>\n<h1><b>Validation of Genetic Stability<\/b><\/h1>\n<p><span style=\"font-weight: 400;\">One of the most common concerns associated with cell therapy is the potential risk of genetic alterations that could contribute to malignant transformation.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">At ReoCell, this risk is minimized through comprehensive monitoring of genetic integrity throughout the manufacturing process.<\/span><\/p>\n<h2><b>G-Banding Karyotype Analysis<\/b><\/h2>\n<p><b>G-banding<\/b><span style=\"font-weight: 400;\"> is a standard cytogenetic technique used to visualize all 46 human chromosomes and detect chromosomal abnormalities.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">This method enables the identification of both:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>numerical abnormalities (aneuploidies);<\/b><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>structural abnormalities<\/b><span style=\"font-weight: 400;\">, including translocations, duplications, deletions, and inversions.<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">Because certain genetic alterations may remain undetectable by conventional cytogenetic analysis alone, current recommendations support combining <\/span><b>G-banding<\/b><span style=\"font-weight: 400;\"> with complementary molecular techniques to improve analytical sensitivity.<\/span><\/p>\n<h2><b>Monitoring the Risk of Spontaneous Transformation During Extended <\/b><b><i>In Vitro<\/i><\/b><b> Expansion<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">Prolonged cell culture may lead to progressive genetic and epigenetic instability, including:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">an increased proportion of cells with abnormal karyotypes;<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">a higher risk of malignant transformation;<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">reduced proliferative and regenerative capacity;<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">morphological changes characterized by a predominance of fibroblast-like cells.<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">To preserve genomic stability, ReoCell routinely performs karyotype analysis, monitors cellular morphology, and limits the number of culture passages used for clinical manufacturing.<\/span><\/p>\n<h1><b>Functional Potency Assessment<\/b><\/h1>\n<p><span style=\"font-weight: 400;\">Confirming the identity and safety of MSCs is only one aspect of quality control. Equally important is demonstrating that the cells retain their biological functionality.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The latest <\/span><b>ISCT (2023\u20132025)<\/b><span style=\"font-weight: 400;\"> recommendations emphasize comprehensive <\/span><b>potency assessment<\/b><span style=\"font-weight: 400;\">, often referred to as the <\/span><b>potency matrix<\/b><span style=\"font-weight: 400;\">, which integrates functional and molecular assays to evaluate the therapeutic capacity of MSCs.<\/span><\/p>\n<h2><b>Proliferation Kinetics: Population Doubling Time (PDT) and Cell Cycle Analysis<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">One of the most important indicators of MSC quality is their proliferative capacity. This parameter is commonly evaluated using <\/span><b>Population Doubling Time (PDT)<\/b><span style=\"font-weight: 400;\">, which represents the time required for a cell population to double in number.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">PDT is calculated using the following formula:<\/span><\/p>\n<p><b>PDT = (t \u00d7 log 2) \/ (log Nf \u2013 log N\u2080)<\/b><\/p>\n<p><span style=\"font-weight: 400;\">where:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>t<\/b><span style=\"font-weight: 400;\"> \u2013 culture time (hours);<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>N\u2080<\/b><span style=\"font-weight: 400;\"> \u2013 initial cell number;<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Nf<\/b><span style=\"font-weight: 400;\"> \u2013 final cell number.<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">Young, highly functional MSCs typically exhibit a PDT of <\/span><b>24\u201348 hours<\/b><span style=\"font-weight: 400;\">. As the number of culture passages increases, PDT gradually extends to <\/span><b>72\u201396 hours or longer<\/b><span style=\"font-weight: 400;\">, reflecting progressive cellular aging and reduced proliferative capacity.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">For clinical applications, ReoCell uses MSCs with a <\/span><b>PDT of less than 60 hours<\/b><span style=\"font-weight: 400;\">, ensuring high proliferative activity and optimal regenerative potential.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Flow cytometry is further employed to analyze the distribution of cells across different phases of the cell cycle (G0\/G1, S, and G2\/M) by measuring cellular DNA content.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Healthy young MSCs typically demonstrate the following distribution:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>G0\/G1:<\/b><span style=\"font-weight: 400;\"> 60\u201375%<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>S phase:<\/b><span style=\"font-weight: 400;\"> 15\u201325%<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>G2\/M:<\/b><span style=\"font-weight: 400;\"> 5\u201310%<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">Significant deviations from these ranges may indicate cellular stress, senescence, or other functional abnormalities.<\/span><\/p>\n<h2><b>Colony-Forming Capacity (CFU-F Assay)<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">The <\/span><b>Colony-Forming Unit-Fibroblast (CFU-F) assay<\/b><span style=\"font-weight: 400;\"> remains one of the reference methods for evaluating the self-renewal capacity and proliferative potential of mesenchymal stem cells.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">MSCs are seeded at a very low density (approximately <\/span><b>1\u201310 cells\/cm\u00b2<\/b><span style=\"font-weight: 400;\">) in culture vessels. Individual cells proliferate independently, giving rise to visible colonies, each originating from a single progenitor cell.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The number of colonies formed directly reflects the clonogenic potential of the MSC population.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Young, healthy MSCs typically demonstrate a <\/span><b>CFU-F efficiency of 20\u201340%<\/b><span style=\"font-weight: 400;\">, meaning that 20\u201340 colonies are formed for every 100 cells seeded.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">By the fifth culture passage, this value generally declines to <\/span><b>5\u201315%<\/b><span style=\"font-weight: 400;\">, indicating progressive loss of self-renewal capacity associated with cellular aging.<\/span><\/p>\n<h2><b>Assessment of Multipotent Differentiation<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">Multipotency is one of the defining biological characteristics of mesenchymal stem cells and refers to their ability to differentiate into three mesenchymal lineages:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">osteogenic;<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">chondrogenic;<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">adipogenic.<\/span><\/li>\n<\/ul>\n<h3><b>Osteogenic Differentiation<\/b><\/h3>\n<p><span style=\"font-weight: 400;\">To confirm osteogenic differentiation, MSCs are cultured in osteogenic induction medium containing:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">L-ascorbic acid;<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">\u03b2-glycerophosphate;<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">dexamethasone.<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">Successful differentiation is confirmed by the formation of mineralized extracellular matrix.<\/span><\/p>\n<h3><b>Chondrogenic Differentiation<\/b><\/h3>\n<p><span style=\"font-weight: 400;\">Chondrogenic potential is assessed by culturing MSCs under hypoxic conditions in the presence of <\/span><b>transforming growth factor-\u03b23 (TGF-\u03b23)<\/b><span style=\"font-weight: 400;\">, which stimulates cartilage matrix formation.<\/span><\/p>\n<h3><b>Adipogenic Differentiation<\/b><\/h3>\n<p><span style=\"font-weight: 400;\">Adipogenic differentiation is induced using culture medium supplemented with:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">insulin;<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">dexamethasone;<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">IBMX (3-isobutyl-1-methylxanthine);<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">indomethacin.<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">Successful differentiation is confirmed by intracellular lipid accumulation characteristic of mature adipocytes.<\/span><\/p>\n<h1><b>Technological Limitations: Passage Number and the Prevention of Replicative Senescence<\/b><\/h1>\n<p><span style=\"font-weight: 400;\">Each cycle of cell expansion and transfer into a new culture vessel is referred to as a <\/span><b>cell passage<\/b><span style=\"font-weight: 400;\">. According to the <\/span><b>Hayflick limit<\/b><span style=\"font-weight: 400;\">, normal human cells can undergo approximately <\/span><b>40\u201360 population doublings<\/b><span style=\"font-weight: 400;\"> before entering a state of <\/span><b>replicative senescence<\/b><span style=\"font-weight: 400;\">, in which they progressively lose their functional properties.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Senescent MSCs are characterized by:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">reduced differentiation capacity;<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">decreased secretory activity;<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">increased production of pro-inflammatory cytokines;<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">diminished resistance to oxidative stress.<\/span><\/li>\n<\/ul>\n<table style=\"width:100%;border-collapse:collapse;margin:1.5em 0;font-size:.95em\">\n<thead>\n<tr>\n<th style=\"border:1px solid #d0d0d0;padding:10px 12px;text-align:left;background:#f5f5f5;font-weight:600\">Passage<\/th>\n<th style=\"border:1px solid #d0d0d0;padding:10px 12px;text-align:left;background:#f5f5f5;font-weight:600\">PDT (hours)<\/th>\n<th style=\"border:1px solid #d0d0d0;padding:10px 12px;text-align:left;background:#f5f5f5;font-weight:600\">CFU-F (%)<\/th>\n<th style=\"border:1px solid #d0d0d0;padding:10px 12px;text-align:left;background:#f5f5f5;font-weight:600\">Multipotency<\/th>\n<th style=\"border:1px solid #d0d0d0;padding:10px 12px;text-align:left;background:#f5f5f5;font-weight:600\">Cell Quality<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #d0d0d0;padding:10px 12px;vertical-align:top\"><b>P1\u2013P2<\/b><\/td>\n<td style=\"border:1px solid #d0d0d0;padding:10px 12px;vertical-align:top\">24\u201336<\/td>\n<td style=\"border:1px solid #d0d0d0;padding:10px 12px;vertical-align:top\">35\u201340<\/td>\n<td style=\"border:1px solid #d0d0d0;padding:10px 12px;vertical-align:top\">Full (+++)<\/td>\n<td style=\"border:1px solid #d0d0d0;padding:10px 12px;vertical-align:top\">Optimal<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #d0d0d0;padding:10px 12px;vertical-align:top;background:#fafafa\"><b>P3\u2013P5<\/b><\/td>\n<td style=\"border:1px solid #d0d0d0;padding:10px 12px;vertical-align:top;background:#fafafa\">36\u201348<\/td>\n<td style=\"border:1px solid #d0d0d0;padding:10px 12px;vertical-align:top;background:#fafafa\">20\u201330<\/td>\n<td style=\"border:1px solid #d0d0d0;padding:10px 12px;vertical-align:top;background:#fafafa\">Full (+++)<\/td>\n<td style=\"border:1px solid #d0d0d0;padding:10px 12px;vertical-align:top;background:#fafafa\">High<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #d0d0d0;padding:10px 12px;vertical-align:top\"><b>P6\u2013P7<\/b><\/td>\n<td style=\"border:1px solid #d0d0d0;padding:10px 12px;vertical-align:top\">48\u201372<\/td>\n<td style=\"border:1px solid #d0d0d0;padding:10px 12px;vertical-align:top\">10\u201320<\/td>\n<td style=\"border:1px solid #d0d0d0;padding:10px 12px;vertical-align:top\">Preserved (++)<\/td>\n<td style=\"border:1px solid #d0d0d0;padding:10px 12px;vertical-align:top\">Acceptable<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #d0d0d0;padding:10px 12px;vertical-align:top;background:#fafafa\"><b>P8+<\/b><\/td>\n<td style=\"border:1px solid #d0d0d0;padding:10px 12px;vertical-align:top;background:#fafafa\">&gt;72<\/td>\n<td style=\"border:1px solid #d0d0d0;padding:10px 12px;vertical-align:top;background:#fafafa\">&lt;10<\/td>\n<td style=\"border:1px solid #d0d0d0;padding:10px 12px;vertical-align:top;background:#fafafa\">Reduced (+)<\/td>\n<td style=\"border:1px solid #d0d0d0;padding:10px 12px;vertical-align:top;background:#fafafa\">Unsuitable for clinical use<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><span style=\"font-weight: 400;\">As shown above, the optimal window for clinical application is within the <\/span><b>first five to seven passages<\/b><span style=\"font-weight: 400;\">, when MSCs retain their highest proliferative capacity, multipotency, and regenerative potential.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">For this reason, ReoCell strictly limits the number of culture passages, routinely monitors senescence-associated markers, and uses only <\/span><b>early-passage MSCs<\/b><span style=\"font-weight: 400;\"> for clinical applications.<\/span><\/p>\n<h1><b>International Standards for MSC Biobanking<\/b><\/h1>\n<p><span style=\"font-weight: 400;\">Long-term storage and management of mesenchymal stem cell products are governed by internationally recognized quality standards, including <\/span><b>ISO\/TS 22859:2022<\/b><span style=\"font-weight: 400;\"> and <\/span><b>ISO 24651:2022<\/b><span style=\"font-weight: 400;\">.<\/span><\/p>\n<h2><b>ISO\/TS 22859:2022<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">This standard establishes quality requirements for handling viable human cells and covers:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">sample labeling and identification;<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">full traceability throughout the manufacturing process;<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">documentation and event logging;<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">data management and confidentiality.<\/span><\/li>\n<\/ul>\n<h2><b>ISO 24651:2022<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">This standard provides guidance for the cryopreservation and long-term storage of MSCs, including:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">the use of <\/span><b>dimethyl sulfoxide (DMSO)<\/b><span style=\"font-weight: 400;\"> as a cryoprotective agent;<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">controlled-rate freezing;<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">storage at <\/span><b>\u2212196\u00b0C<\/b><span style=\"font-weight: 400;\"> in liquid nitrogen or <\/span><b>\u221280\u00b0C<\/b><span style=\"font-weight: 400;\"> under validated conditions;<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">standardized thawing procedures;<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">post-thaw viability assessment, with a recommended viability of <\/span><b>\u226580%<\/b><span style=\"font-weight: 400;\"> for clinical application.<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">At ReoCell, both standards are integrated into the quality management system, ensuring consistent product quality, long-term stability, and full traceability throughout the entire biobanking process.<\/span><\/p>\n<h1><b>Conclusion<\/b><\/h1>\n<p><span style=\"font-weight: 400;\">The clinical success of mesenchymal stem cell therapy begins long before treatment. It depends on rigorous donor selection, comprehensive quality control, continuous monitoring of genetic stability, functional potency assessment, and strict compliance with internationally recognized manufacturing and biobanking standards.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Every stage\u2014from donor screening and cell expansion to cryopreservation and final product release\u2014contributes to the safety, consistency, and therapeutic potential of MSC-based therapies.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">By implementing internationally recognized quality standards, ReoCell ensures that each MSC product meets stringent requirements for identity, purity, genetic stability, and biological functionality, providing a reliable foundation for safe and effective regenerative medicine.<\/span><\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>In modern regenerative medicine, mesenchymal stem cells (MSCs) represent one of the most promising therapeutic platforms, offering new opportunities for the treatment of traumatic injuries, degenerative disorders, and autoimmune diseases. However, the clinical effectiveness of MSC-based therapy depends primarily on the quality of the starting [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":2169,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"post-type":[],"post-whom":[],"service":[],"material":[],"whom":[],"class_list":["post-2166","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-bez-kategoriyi"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Quality Control of Mesenchymal Stem Cells: Donor Selection, Genetic Stability, and Proliferative Potential - Reocell<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/reocell.com\/en\/blog\/quality-control-of-mesenchymal-stem-cells-donor-selection-genetic-stability-and-proliferative-potential\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Quality Control of Mesenchymal Stem Cells: Donor Selection, Genetic Stability, and Proliferative Potential - Reocell\" \/>\n<meta property=\"og:description\" content=\"In modern regenerative medicine, mesenchymal stem cells (MSCs) represent one of the most promising therapeutic platforms, offering new opportunities for the treatment of traumatic injuries, degenerative disorders, and autoimmune diseases. However, the clinical effectiveness of MSC-based therapy depends primarily on the quality of the starting [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/reocell.com\/en\/blog\/quality-control-of-mesenchymal-stem-cells-donor-selection-genetic-stability-and-proliferative-potential\/\" \/>\n<meta property=\"og:site_name\" content=\"Reocell\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-17T11:21:21+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-17T11:37:55+00:00\" \/>\n<meta name=\"author\" content=\"SEO MedUP\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"SEO MedUP\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"9 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/reocell.com\\\/en\\\/blog\\\/quality-control-of-mesenchymal-stem-cells-donor-selection-genetic-stability-and-proliferative-potential\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/reocell.com\\\/en\\\/blog\\\/quality-control-of-mesenchymal-stem-cells-donor-selection-genetic-stability-and-proliferative-potential\\\/\"},\"author\":{\"name\":\"SEO MedUP\",\"@id\":\"https:\\\/\\\/reocell.com\\\/en\\\/#\\\/schema\\\/person\\\/44bee65b347c032c71d4a04c1bf7423d\"},\"headline\":\"Quality Control of Mesenchymal Stem Cells: Donor Selection, Genetic Stability, and Proliferative Potential\",\"datePublished\":\"2026-07-17T11:21:21+00:00\",\"dateModified\":\"2026-07-17T11:37:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/reocell.com\\\/en\\\/blog\\\/quality-control-of-mesenchymal-stem-cells-donor-selection-genetic-stability-and-proliferative-potential\\\/\"},\"wordCount\":1607,\"image\":{\"@id\":\"https:\\\/\\\/reocell.com\\\/en\\\/blog\\\/quality-control-of-mesenchymal-stem-cells-donor-selection-genetic-stability-and-proliferative-potential\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/reocell.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/quality_control.png\",\"articleSection\":[\"\u0411\u0435\u0437 \u043a\u0430\u0442\u0435\u0433\u043e\u0440\u0456\u0457\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/reocell.com\\\/en\\\/blog\\\/quality-control-of-mesenchymal-stem-cells-donor-selection-genetic-stability-and-proliferative-potential\\\/\",\"url\":\"https:\\\/\\\/reocell.com\\\/en\\\/blog\\\/quality-control-of-mesenchymal-stem-cells-donor-selection-genetic-stability-and-proliferative-potential\\\/\",\"name\":\"Quality Control of Mesenchymal Stem Cells: Donor Selection, Genetic Stability, and Proliferative Potential - Reocell\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/reocell.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/reocell.com\\\/en\\\/blog\\\/quality-control-of-mesenchymal-stem-cells-donor-selection-genetic-stability-and-proliferative-potential\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/reocell.com\\\/en\\\/blog\\\/quality-control-of-mesenchymal-stem-cells-donor-selection-genetic-stability-and-proliferative-potential\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/reocell.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/quality_control.png\",\"datePublished\":\"2026-07-17T11:21:21+00:00\",\"dateModified\":\"2026-07-17T11:37:55+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/reocell.com\\\/en\\\/#\\\/schema\\\/person\\\/44bee65b347c032c71d4a04c1bf7423d\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/reocell.com\\\/en\\\/blog\\\/quality-control-of-mesenchymal-stem-cells-donor-selection-genetic-stability-and-proliferative-potential\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/reocell.com\\\/en\\\/blog\\\/quality-control-of-mesenchymal-stem-cells-donor-selection-genetic-stability-and-proliferative-potential\\\/#primaryimage\",\"url\":\"https:\\\/\\\/reocell.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/quality_control.png\",\"contentUrl\":\"https:\\\/\\\/reocell.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/quality_control.png\",\"width\":1672,\"height\":941},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/reocell.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/reocell.com\\\/en\\\/\",\"name\":\"Reocell\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/reocell.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/reocell.com\\\/en\\\/#\\\/schema\\\/person\\\/44bee65b347c032c71d4a04c1bf7423d\",\"name\":\"SEO MedUP\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Quality Control of Mesenchymal Stem Cells: Donor Selection, Genetic Stability, and Proliferative Potential - Reocell","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/reocell.com\/en\/blog\/quality-control-of-mesenchymal-stem-cells-donor-selection-genetic-stability-and-proliferative-potential\/","og_locale":"en_US","og_type":"article","og_title":"Quality Control of Mesenchymal Stem Cells: Donor Selection, Genetic Stability, and Proliferative Potential - Reocell","og_description":"In modern regenerative medicine, mesenchymal stem cells (MSCs) represent one of the most promising therapeutic platforms, offering new opportunities for the treatment of traumatic injuries, degenerative disorders, and autoimmune diseases. However, the clinical effectiveness of MSC-based therapy depends primarily on the quality of the starting [&hellip;]","og_url":"https:\/\/reocell.com\/en\/blog\/quality-control-of-mesenchymal-stem-cells-donor-selection-genetic-stability-and-proliferative-potential\/","og_site_name":"Reocell","article_published_time":"2026-07-17T11:21:21+00:00","article_modified_time":"2026-07-17T11:37:55+00:00","author":"SEO MedUP","twitter_card":"summary_large_image","twitter_misc":{"Written by":"SEO MedUP","Est. reading time":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/reocell.com\/en\/blog\/quality-control-of-mesenchymal-stem-cells-donor-selection-genetic-stability-and-proliferative-potential\/#article","isPartOf":{"@id":"https:\/\/reocell.com\/en\/blog\/quality-control-of-mesenchymal-stem-cells-donor-selection-genetic-stability-and-proliferative-potential\/"},"author":{"name":"SEO MedUP","@id":"https:\/\/reocell.com\/en\/#\/schema\/person\/44bee65b347c032c71d4a04c1bf7423d"},"headline":"Quality Control of Mesenchymal Stem Cells: Donor Selection, Genetic Stability, and Proliferative Potential","datePublished":"2026-07-17T11:21:21+00:00","dateModified":"2026-07-17T11:37:55+00:00","mainEntityOfPage":{"@id":"https:\/\/reocell.com\/en\/blog\/quality-control-of-mesenchymal-stem-cells-donor-selection-genetic-stability-and-proliferative-potential\/"},"wordCount":1607,"image":{"@id":"https:\/\/reocell.com\/en\/blog\/quality-control-of-mesenchymal-stem-cells-donor-selection-genetic-stability-and-proliferative-potential\/#primaryimage"},"thumbnailUrl":"https:\/\/reocell.com\/wp-content\/uploads\/2026\/07\/quality_control.png","articleSection":["\u0411\u0435\u0437 \u043a\u0430\u0442\u0435\u0433\u043e\u0440\u0456\u0457"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/reocell.com\/en\/blog\/quality-control-of-mesenchymal-stem-cells-donor-selection-genetic-stability-and-proliferative-potential\/","url":"https:\/\/reocell.com\/en\/blog\/quality-control-of-mesenchymal-stem-cells-donor-selection-genetic-stability-and-proliferative-potential\/","name":"Quality Control of Mesenchymal Stem Cells: Donor Selection, Genetic Stability, and Proliferative Potential - Reocell","isPartOf":{"@id":"https:\/\/reocell.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/reocell.com\/en\/blog\/quality-control-of-mesenchymal-stem-cells-donor-selection-genetic-stability-and-proliferative-potential\/#primaryimage"},"image":{"@id":"https:\/\/reocell.com\/en\/blog\/quality-control-of-mesenchymal-stem-cells-donor-selection-genetic-stability-and-proliferative-potential\/#primaryimage"},"thumbnailUrl":"https:\/\/reocell.com\/wp-content\/uploads\/2026\/07\/quality_control.png","datePublished":"2026-07-17T11:21:21+00:00","dateModified":"2026-07-17T11:37:55+00:00","author":{"@id":"https:\/\/reocell.com\/en\/#\/schema\/person\/44bee65b347c032c71d4a04c1bf7423d"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/reocell.com\/en\/blog\/quality-control-of-mesenchymal-stem-cells-donor-selection-genetic-stability-and-proliferative-potential\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/reocell.com\/en\/blog\/quality-control-of-mesenchymal-stem-cells-donor-selection-genetic-stability-and-proliferative-potential\/#primaryimage","url":"https:\/\/reocell.com\/wp-content\/uploads\/2026\/07\/quality_control.png","contentUrl":"https:\/\/reocell.com\/wp-content\/uploads\/2026\/07\/quality_control.png","width":1672,"height":941},{"@type":"WebSite","@id":"https:\/\/reocell.com\/en\/#website","url":"https:\/\/reocell.com\/en\/","name":"Reocell","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/reocell.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/reocell.com\/en\/#\/schema\/person\/44bee65b347c032c71d4a04c1bf7423d","name":"SEO MedUP"}]}},"_links":{"self":[{"href":"https:\/\/reocell.com\/en\/wp-json\/wp\/v2\/posts\/2166","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/reocell.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/reocell.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/reocell.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/reocell.com\/en\/wp-json\/wp\/v2\/comments?post=2166"}],"version-history":[{"count":0,"href":"https:\/\/reocell.com\/en\/wp-json\/wp\/v2\/posts\/2166\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/reocell.com\/en\/wp-json\/wp\/v2\/media\/2169"}],"wp:attachment":[{"href":"https:\/\/reocell.com\/en\/wp-json\/wp\/v2\/media?parent=2166"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/reocell.com\/en\/wp-json\/wp\/v2\/categories?post=2166"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/reocell.com\/en\/wp-json\/wp\/v2\/tags?post=2166"},{"taxonomy":"post-type","embeddable":true,"href":"https:\/\/reocell.com\/en\/wp-json\/wp\/v2\/post-type?post=2166"},{"taxonomy":"post-whom","embeddable":true,"href":"https:\/\/reocell.com\/en\/wp-json\/wp\/v2\/post-whom?post=2166"},{"taxonomy":"service","embeddable":true,"href":"https:\/\/reocell.com\/en\/wp-json\/wp\/v2\/service?post=2166"},{"taxonomy":"material","embeddable":true,"href":"https:\/\/reocell.com\/en\/wp-json\/wp\/v2\/material?post=2166"},{"taxonomy":"whom","embeddable":true,"href":"https:\/\/reocell.com\/en\/wp-json\/wp\/v2\/whom?post=2166"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}